Guerrero MAI, Aguilar LL, Rubio JB

Language: Spanish
References: 18
Page: 88-92
PDF size: 35.74 Kb.

ABSTRACT

Multiple myeloma (MM) is a disorder characterized by clonal proliferation of plasma cells and the presence of a monoclonal protein (M protein) (IgG, IgA, IgD or IgE) and light chains (kappa/lambda) in serum or urine. The incidence is 0.2 to 5.1 cases per 100,000 population per year, corresponding to 1-2% of all malignancies and 10% of hematologic malignancies. There impaired immunity in these patients, T lymphocyte function affects other cellular components, some cytokines such as IL-2, IL-6 involved in the proliferation and differentiation of B cells involved in the pathophysiology of multiple myeloma. Patients with multiple myeloma are at increased risk of venous thromboembolism (VTE), particularly as treated with immunomodulators (thalidomide, lenalidomide) in combination with steroids (dexamethasone), chemotherapy or erythropoietin, with an incidence that can be up to 35%. The pathophysiology of procoagulant state in multiple myeloma is related to the elevation of factor VIII, von Willebrand factor and acquired resistance to activated protein C. It is important to know the relationship of biological systems of inflammation, immunity and hemostasis with this neoplasm and its activation as markers of a clinical spectrum.

REFERENCES

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Eng J Med 2004; 351: 1860-1873.

2. Augustson BM, Begum G, Dunn J, Barth NJ, Davies F, Morgan G et al. Early mortality after diagnosis of multiple myeloma: Analysis of patients entered onto the United Kingdom Medical Research Council Trials between 1980 and 2002-Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005; 23: 9219-9226.

3. Aggarwal B Gehlot P et al. Inflammation and cancer: how friendly is the relationship for cancer patients. Curr Opin Pharmacol 2009; 9: 351-369.

4. Abdi J, Engels F, Garssen J, Redegeld F. The role of Toll-like receptor mediated signalling in the pathogenesis of multiple myeloma. Crit Rev Oncol Hematol 2011; 80: 225-240.

5. Hungria VTM, Maiolino A, Martínez G, Coelho EOM, Bittencourt R, Souza CA et al. South American multiple myeloma study: Epidemiological and clinical characteristics of 751 patients. Haematologica/Hematol J 2005; 90 (suppl 1): 120-121.

6. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-757.

7. Conroy A, Stockett DE, Walker D, Arkin et al. SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemother Pharmacol 2009; 64(4): 723-732.

8. Lacrima K, Rinaldi A, Vignati S, Martin V et al. Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas. Leukaemia & Lymphoma 2007; 48: 158-167.

9. Dispenzieri A, Lacy M, Greipp P. Multiple Myeloma. In: Greer JP, Foerster J, Lukens JN, Rodgers GM, Paraskevas F, Glader BE (eds). Wintrobe’s Clinical Hematology. 11th ed. Philadelphia, PA: Lippincot Williams and Wilkins; 2004: 2583-2636.

10. Anderson KC, Pazdurn R, Farrell AT. Development of Effective New Treatments for Multiple Myeloma. J Clin Oncol 2005; 23: 7207-7211.

11. Boylan KL, Gosse MA, Staggs SE, Janz S, Grindle S et al. A transgenic mouse model of plasma cell malignancy shows phenotypic, cytogenetic, and gene expression heterogeneity similar to human multiple myeloma. Cancer Res 2007; 67: 4069-4078.

12. Chesi M, Robbiani DF, Sebag M, Chng WJ, Affer M et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 2008; 13: 167-180.

13. Zhou X, Jiang H, Hou J. Coordination of upregulated XBP-1 and downregulated c-myc during myeloma cell differentiation induced by 2-methoxyestradiol. Leuk Res 2007; 31: 1259-1265.

14. Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G et al. IRF4 addiction in multiple myeloma. Nature 2008; 454: 226-231.

15. Shaffer AL, Emre NC, Romesser PB, Staudt LM et al. IRF4: Immunity. Malignancy therapy. Clin Cancer Res 2009; 15: 2954-2961.

16. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression. Br J Haematol 2007; 139: 730-743.

17. Blade J, Rosinol L, Cibeira MT, de Larrea CF. Pathogenesis and progression of monoclonal gammopathy of undetermined significance. Leukemia 2008; 22: 1651-1657.

18. Zamagni E, Brioli A et al. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. Semin Thromb Hemost 2011; 37(3): 209-292.